Products for Research Use Only

Laquinimod-d5

CAT: 0804-HY-13010S-01Size: 1 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-13010S-01Size:1 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Laquinimod-d5 (ABR-215062-d5) is deuterium labeled Laquinimod. Laquinimod (ABR-215062), an orally available carboxamide derivative, is a potent immunomodulator that prevents neurodegeneration and inflammation in the central nervous system. Laquinimod reduces astrocytic NF-κB activation to protect from Cuprizone-induced demyelination. Laquinimod has the potential for relapsing-remitting (RR) and chronic progressive (CP) forms of multiple sclerosis (MS; RRMS or CPMS) as well as neurodegenerative diseases research[1].
CAS Number
1214267-09-0
Product Name Alternative
ABR-215062-d5
UNSPSC
12352005
Target
Apoptosis; Isotope-Labeled Compounds; NF-κB
Type
Isotope-Labeled Compounds
Related Pathways
Apoptosis; NF-κB; Others
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology
Purity
98.25
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
[2H]C1=C([2H])C([2H])=C(N(C(C2=C(O)C3=C(N(C)C2=O)C=CC=C3Cl)=O)CC)C([2H])=C1[2H]
Molecular Formula
C19H12D5ClN2O3
Molecular Weight
361.83
References & Citations
[1]Varrin-Doyer M, et al. Laquinimod, an up-and-coming immunomodulatory agent for treatment of multiple sclerosis. Exp Neurol. 2014 Dec;262 Pt A:66-71.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Isotope-Labeled Compounds
Clinical Information
No Development Reported